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Background
The incidence of prostate cancer is increasing and accounts for 
25% of cancer diagnosis in men in the United Kingdom1 and 
8% of all cancer cases worldwide as of 2012.2 The rising inci-
dence is partly due to an ageing population and is also second-
arily related to routine testing for serum prostate-specific 
antigen (PSA). Although PSA testing can detect prostate can-
cers at an early stage, some of which will be clinically relevant, 
the test has the drawback that it cannot accurately differentiate 
between indolent tumours (the majority of cases) and aggres-
sive disease. Consequently, there is a risk of overdiagnosis and 
overuse of radical treatments for indolent tumours3 and under-
use of strategies to avoid or delay radical treatments, such as 
active monitoring. There is thus a major clinical need for novel 
prognostic prostate cancer biomarkers that can discriminate 
better between early-stage indolent prostate tumours and those 
that are likely to progress and metastasise.4,5
In general, the ability of carcinomas to spread locally and 
later establish metastases is linked to an increased functional 
capacity of the tumour cells to migrate and invade the nearby 
tissue, lymph nodes, or local blood vessels. These properties 
relate in large part to altered expression of cell adhesion mole-
cules and cytoskeletal proteins.6 Fascin-1 is an actin-bundling 
protein which is not expressed in most adult human epithelia 
but which becomes upregulated in many carcinomas.7–11 To 
date, fascin-1 has been studied most extensively in carcinomas 
of the breast, colon, lung, oesophagus, and stomach. In a com-
prehensive systematic review and meta-analysis, fascin-1 was 
found to correlate with increased risk of mortality in primary 
carcinomas of the colon, breast, and oesophagus; with risk of 
disease progression in breast and colorectal cancers; and with 
risk of local or distant metastasis in colorectal carcinoma.12 
Since the publication of this meta-analysis, fascin-1 has been 
correlated with pancreatic cancer progression, although no 
meta-analysis has yet been performed.13,14
The importance of fascin-1 in carcinoma progression has 
been demonstrated experimentally in several mouse models. 
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Knock-down of the fascin-1 transcript in human colon or 
prostate carcinoma cell lines led to decreased xenograft tumour 
growth and metastasis in mice,15,16 whereas specific overex-
pression of fascin-1 in the intestine promoted colorectal 
tumour growth.17 Fascin-1 also promoted tumour progression 
in a mouse genetic model of pancreatic cancer.13 More recently, 
a small molecule that inhibits actin bundling by fascin-1 was 
reported to decrease lung metastasis of syngeneic fascin-1–pos-
itive breast tumours in mice.18 Therefore, fascin-1 has emerged 
as a new prospective therapeutic target.19,20
Information on the relevance of fascin-1 to prostate cancer 
is limited. The first study of human prostate cancer specimens 
correlated increased fascin-1 protein with localised and hor-
mone refractory prostate cancer compared with uninvolved 
tissue.16 Studies of prostate cancer cell lines also demonstrated 
that FSCN1 messenger RNA (mRNA) is a target of miR-145, 
a microRNA that is downregulated in prostate cancer, thus 
leading to elevation of FSCN1 mRNA. Silencing of the FSCN1 
transcript in these cell lines resulted in decreased cell migra-
tion, invasion, and proliferation.21 Similarly, a nanobody that, 
when introduced into cells, perturbs the binding of fascin-1 to 
F-actin, inhibited assembly of invadopodia and cell invasion in 
PC3 prostate cancer cells.22 Although these studies implicate 
similar functional roles of fascin-1 in prostate carcinoma cells 
as in colon or breast carcinoma cells, further studies of inde-
pendent sets of human prostate tumour specimens are crucially 
needed to evaluate whether fascin-1 might be suitable as a bio-
marker to distinguish aggressive from indolent prostate carci-
nomas at an early stage.
Here, we present the results of an analysis of fascin-1 by 
immunohistochemistry in prostate carcinoma specimens from 
the Wales Cancer Bank (WCB). Immunohistochemistry was 
performed on conventional sections of prostate tumours and 
on a new tissue microarray (TMA) that comprised 211 tumours 
that included specimens of low, intermediate, or high Gleason 
risk scores. We also investigated the relationship between fas-
cin-1 and nuclear-located ETS-related gene (ERG) protein. 
The TMPRSS2-ERG gene fusion is detected in around 50% of 
prostate cancers and correlates with aggressive disease progres-
sion.23,24 Overexpression of truncated ERG protein in nuclei is 
detectable by immunohistochemistry and correlates well with 
occurrence of the gene fusion.25,26 Functional consequences of 
TMPRSS2-ERG expression include increased cell migration.27 
Thus, it was of interest to assess fascin-1 by immunohisto-
chemistry against ERG because the latter is an emerging 
marker of aggressive prostate cancer progression and because of 
the possibility that stimulation of cell migration by TMPRSS2-
ERG might be a fascin-1–dependent process.
Methods
Patients and surgical specimens
All specimens were obtained as anonymised samples from the 
WCB (www.walescancerbank.com) as sections prepared from 
formalin-fixed, paraffin-embedded prostate tumour biopsies. 
For the conventional sections, 20 specimens were selected at 
random from the eligible specimens in WCB as examples of 
low/intermediate (Gleason score 6 [n = 4] or 7 [n = 6]) or high 
(Gleason score 8 [n = 8], score 9 [n = 1], or score 10 [n = 1]) risk 
tumours and examined as 4 µm thick sections. Two samples of 
uninvolved tissues were analysed as controls.
A TMA of prostate tumour samples was constructed by the 
WCB using a semi-automated TMA Master (3DHISTECH; 
http://www.3dhistech.com/tma_master) and 0.6 mm diameter 
cores. The TMA contained 211 prostate samples of low, inter-
mediate, and high Gleason risk scores from 158 patients; for 53 
patients, including those with multi-focal disease, multiple 
samples from different locations had been taken (Supplementary 
Datafile). In all, 145 samples were from prostatectomy speci-
mens and 66 were from trans-rectal, ultrasound-guided needle 
core biopsies. The median age of the patients was 65 years 
(range: 40-86 years) with a 5-year median follow-up. The path-
ological grading of the samples according to Gleason risk 
score and available patient data are summarised in Table 1. 
19 samples were from 18 patients who subsequently developed 
biochemical relapse following surgery. Biochemical relapse was 
defined as a PSA rise of greater than 0.2 ng/mL following sur-
gery. Because only 4 patients died in the follow-up period, no 
meaningful mortality analysis could be undertaken. Each 
patient sample was assigned a unique ID number by WCB, and 
each sample ID included this number and a TMA location 
number. Sample IDs were subsequently linked to a database 
of demographic and clinico-pathological data. The Gleason 
score of each core was quality assured by a consultant uro- 
histopathologist in accordance with the 2005 International 
Society of Urological Pathology (ISUP) Consensus Conference 
on Gleason Grading of prostate carcinoma.28 These studies 
were approved under the Human Tissue Act (HTA) (WCB 
project number 13/014 for the conventional sections and 
12/007 for the TMA).
Immunohistochemistry
For specimens examined as conventional sections, slides were 
de-waxed in Histoclear (National Diagnostics, Atlanta, USA) 
followed by re-hydration by sequential washes in 100% and 
70% ethanol and then water. Antigen retrieval was carried out 
in hot 10 mM sodium citrate buffer at pH 6.0 for 20 minutes. 
Immunohistochemistry was performed with a mouse mono-
clonal antibody to fascin-1 (clone 55k2; Dako, Denmark) at 
1:50 dilution for 30 minutes, followed by Vectastain Universal 
Elite ABC immunohistochemistry kit (with 1:100 dilution of 
secondary antibody) and ImmPACT DAB peroxidase sub-
strate detection reagent (all from Vector Labs, Peterborough, 
UK). Slides were then washed in cold running water for 
5 minutes and counter-stained in Gill’s hematoxylin (Sigma-
Aldrich, Gillingham, UK). A secondary antibody–only con-
trol was included in each set of slides stained to assess any 
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background diaminobenzidine tetrahydrochloride (DAB) 
reactivity. Images were taken under the 4× bright-field objec-
tive of a Leica DMI4000B microscope using a Leica DFC410 
FX CCD camera controlled by LAS 3.7 software and were 
exported as tif files. Fascin-1 immunoreactivity of endothelial 
cells in microvessels provided an internal positive control in 
each section. The TMA block was sectioned as 4 µm thick 
sections on SuperFrost Plus slides for experimental immuno-
histochemistry and hematoxylin-eosin staining. The same 
method of fascin-1 staining was used for samples on the 
TMA. ETS-related gene staining of the TMA was performed 
by UCL Advanced Diagnostics (London, UK). Sections 
underwent automated dewaxing, followed by automated 
heat-induced epitope retrieval (HIER) on Leica Bond-III 
(Leica Biosystems) machines. Heat-induced epitope retrieval 
was performed with Leica Bond ER2 (pH 9.0, Cat. No. 
AR9640) for 30 minutes at 100°C. Peroxidase block (part of 
the Leica Bond Refine detection kit, Cat. No. DS9800) was 
applied for 5 minutes, followed by ERG antibody (Epitomics, 
Slough, UK; Clone EP111, Cat. No. AC-0105, diluted 1/150 
in Leica Bond diluent, Cat. No. AR9352) for 15 minutes. 
Sections were then incubated in Leica Bond secondary anti-
body for 8 minutes, followed by Leica Bond Polymer for 
8 minutes. Between each reagent step, sections were rinsed in 
Leica Bond Wash (Cat. No. AR9590) and deionised water. 
Bound antibody was visualised by 10-minute incubation with 
DAB and DAB enhancement with 0.5% copper sulphate for 
5 minutes. Sections were counterstained with hematoxylin for 
45 seconds and dehydrated through graded alcohol, cleared in 
xylene, and mounted in DPX media (Sigma). All TMA slides 
were scanned and photographed with a Zeiss Axio Scan.Z1.
Analysis and scoring of immunohistochemical 
staining
Fascin-1 positivity of tumour cells was defined as cytoplasmic 
staining. Conventional sections were viewed independently, 
blinded to Gleason grade, by 2 observers and scored according 
to the extent of the area of fascin-1 staining within the tumour 
and also the staining intensity relative to uninvolved tissue. 
Fascin-1 positivity of the tumour stroma was assessed in rela-
tion to the stroma of uninvolved tissues. For the TMA, scoring 
for fascin-1 was blinded to Gleason grade and ERG status and 
was based on the proportion of positively stained cells within 
the tumour on a scale from 0 to 3: 0 = no staining; 1 = staining 
of 1% to 25% of cells; 2 = staining of 25% to 50% of cells; 
3 = staining of >50% of cells. Staining of stromal cells was 
assessed visually. Blinded scoring of TMA samples for ERG 
was based on a combined evaluation of intensity (scale 0-3) 
and proportion of tumour cells with nuclear ERG (scale 0-6), 
giving a total scoring range of 0 to 18. Statistical analysis was 
carried out with GraphPad Prism Version 5.0b. The distribu-
tion of the data was checked visually using frequency distribu-
tion graphs (histograms). Both fascin-1 and ERG datasets 
were not normally distributed, so median and interquartile 
ranges (IQR) were computed and are presented as box and 
whisker plots. The Mann-Whitney U test was used to compare 
data between each test group (eg, fascin-1 score between nor-
mal tissue and cancer samples).
Results and Discussion
Fascin-1 is elevated in prostate carcinomas and 
their adjacent stroma and has focal and variable 
localisation patterns
Immunohistochemistry of conventional sections for fascin-1 
demonstrated limited staining of stromal cells or microvascular 
endothelium in samples of uninvolved tissue; these served as a 
positive control for the specificity of the antibody (Figure 1A). 
In low/intermediate-grade (Gleason score 6 or 7) tumour spec-
imens, weak staining for fascin-1 was apparent in stromal cells 
in 8 of the 10 specimens examined (Figure 1B, C). Only a 
minority of the low/intermediate-grade tumours examined (2 
of 10 cases) contained fascin-1–positive tumour cells, and these 
corresponded to <10% of the tumour cells (Figure 1C). High-
grade (Gleason score 8-10) tumours showed wide variability in 
the extent and intensity of fascin-1 staining. In all cases (10 of 
10 samples), there was widespread stromal staining (Figure 1D, 
E). Three tumours also showed fascin-1 staining in focal 
groups of tumour cells (Figure 1D, examples of small areas of 
Table 1. Pathological classification by Gleason risk score and patient cohort information for the prostate tumour specimens on the TMA.
RISK ClASSIFICATION SPECIMENS, 
NO. (%)
AGE IN yEARS, 
MEDIAN (RANGE)
PSA IN NG/Ml, 
MEDIAN (RANGE)
BIOCHEMICAl RECURRENCE 
FOllOWING SURGERy, NO. (%)
Normal 47 (22.2) n/a n/a n/a
low risk (GG ⩽ 6) 74 (35.1) 69 (40–86) 9.1 (2.2–165.0) 7/38 (18.4)
Intermediate risk (GG = 7) 55 (26.1) 65 (43–79) 12.3 (2.2–64) 3/33 (9.1)
High risk (GG ⩾ 8) 35 (16.6) 67 (47–82) 9.5 (2.2–47) 9/24 (37.5)
Total 211 (100) 65 (40–86) 9.7 (2.2–165) 19/95 (20.0)
Abbreviations: GG, Gleason grade; PSA, prostate-specific antigen; TMA, tissue microarray.
The data on PSA and biochemical relapse are figures for the patients. The Gleason scores refer to each core on the TMA.
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fascin-1–positive tumour cells are marked with asterisks). No 
staining was detected in the absence of the primary antibody 
(Figure 1F).
Within the TMA specimen set, fascin-1 staining patterns 
were in agreement with those observed on the conventional 
sections and were for the most part patchy and focal. On the 
TMA, 62% of the samples (n = 131) had fascin-1 staining in 
stromal cells as well as in the epithelial cells, and stromal stain-
ing was frequently more intense than that in the epithelial cells 
(Figure 2B and Supplementary Datafile). As observed in the 
conventional sections, areas of fascin-1–positive glands in 
tumours were often sharply limited, such that a fascin-negative 
gland was surrounded by fascin-positive glands (Figure 2B). 
We conclude that fascin-1 staining of prostate tumours is very 
heterogeneous and includes elevation of fascin-1 in stromal 
cells more commonly than in tumour cells.
Relationship of fascin-1–positive tumour cells or 
stroma to clinico-pathological characteristics of the 
TMA study set
The scoring data for fascin-1 (see ‘Methods’ section) from the 
TMA were analysed in relation to the anonymous clinico-
pathological characteristics of the patients. The fascin-1 score 
for tumour cells tended to be elevated in prostate tumour 
samples relative to the normal prostate tissue, but this did not 
reach statistical significance (median score = 0, IQR 0-1, 
range, 0-3 in the tumour samples, vs median score = 0, IQR 
0-0, range 0-1 in normal prostate tissue, P = .12; Figure 3A). 
A notable limiting factor in the analysis was that relatively 
few tumours (15 of 211 samples on the TMA) included more 
than 10% of tumour cells that were positive for fascin-1. 
When tumour samples were analysed according to Gleason 
risk score (Table 1), elevation of fascin-1 in comparison with 
the normal tissue was not apparent (normal, fascin median 
score = 0, IQR 0-0, range 0-1; low risk: fascin median score = 0, 
IQR 0-1, range 0-3; intermediate risk: fascin median score = 0, 
IQR 0-1, range 0-2; high risk: fascin median score = 0, IQR 
0-1, range 0-3; Figure 3A). Furthermore, there was no trend 
of fascin-1 score with tumour stage (Figure 3B) or with 
patient PSA status at the time of biopsy (Figure 3C). Fascin-1 
score was also examined in relation to biochemical relapse 
after surgery (18 of 145 patients); no relationship was appar-
ent (Figure 3D). Fascin-1 staining was seen more commonly 
in the tumour-associated stroma, with a trend towards a 
higher incidence of positivity seen in high-risk tumours. 
Thus, 53.2% (n = 25) of normal samples, 50.0% (n = 37) of 
low-risk tumours, 70.9% (n = 39) of intermediate-risk 
tumours, and 80.0% (n = 28) of high-risk tumours had ele-
vated stromal fascin-1 staining (Supplementary Datafile). 
There were a greater number of samples with positive stromal 
staining when comparing low Gleason risk versus intermedi-
ate-risk tumours (P = .036), low-risk versus high-risk tumours 
(P = .009), or normal tissue versus high-risk tumours (P = .035) 
(Figure 3E). When accounting for Bonferroni correction for 
these 3 sub-analysis (the statistically significant P-value using 
Bonferroni correction = 0.05/3 = 0.017), only the stromal fas-
cin-1 staining in high-risk tumours compared with low-risk 
tumours reached statistical significance (P = .009). In the 
colon, elevated fascin-1 has been associated with inflamma-
tory states29; it is unknown whether elevated stromal fascin-1 
in prostate tumours might result from inflammatory cues.
Figure 1. Fascin-1 staining patterns in human prostate carcinomas. Examples of fascin-1 staining in conventional sections of prostate carcinomas. (A) 
Uninvolved tissue; (B, C), low/intermediate grade, Gleason score 7 tumours; (D)-(F), high grade, Gleason score 9 tumours. Focal areas of fascin-1–
positive tumour cells are indicated by asterisks in (D). All sections were counter-stained with hematoxylin-eosin.
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Relationship of fascin-1 positivity to nuclear-
located ERG
We next compared the data obtained for fascin-1 in tumour 
cells with an emerging predictive immunohistochemical 
marker of prostate cancer aggressiveness, nuclear ERG. 
TMPRSS2-ERG expression has been related to prostate can-
cer progression and, in mouse models, to increased tumour 
growth and metastasis to bone.30,31 In view that ERG activity 
in prostate cancer cell lines results in increased migratory 
capacity,27 it was also of interest to consider whether fascin-1 
might be upregulated in a TMPRSS2-ERG-dependent path-
way. From staining of the TMA for ERG, 183 of the 211 
specimen cores were informative for ERG staining. Nuclear 
ERG reports on the truncated ERG protein expressed as a 
result of the TMPRSS2-ERG gene fusion that is present in 
approximately 50% of prostate cancers.23–26 In uninvolved tis-
sue, nuclear ERG was detected in only a small number of cells 
and appeared random with regard to cell type and tissue 
organisation (Figure 2C). In contrast, nuclear ERG was clearly 
elevated in the tumour cells of 44% (n = 81) of tumour speci-
mens (Supplementary Datafile). As expected, nuclear ERG 
was restricted to the carcinoma cells and was not detected in 
stromal cells (Figure 2D).
Quantified scoring of nuclear ERG positivity demonstrated 
that nuclear ERG is upregulated in prostate tumours (ERG 
median score = 3, IQR 0-10, range 0-18) compared with nor-
mal prostate epithelium (ERG median score = 0, IQR 0-3, 
range 0-12, P < .001; Figure 4A). Further analyses of the tumour 
samples as a function of Gleason score demonstrated that the 
mean nuclear ERG score was higher in intermediate-risk 
tumours (ERG median score = 5, IQR 0-12, range 0-18) than 
in low-risk tumours (ERG median score = 3, IQR 0-8, range 
0-18, P < .05; Figure 4A). Although the high-risk tumours had 
greater nuclear ERG scores (ERG median score = 4, IQR 0-11, 
range 0-18) than normal tissue (ERG median score = 0, IQR 
0-3, range 0-12, P > .001) or low-risk tumours (ERG median 
score = 3, IQR 0-8, range 0-18), the nuclear ERG score was not 
significantly increased between low- and high-risk tumours 
(Figure 4A). The level of nuclear ERG in high-risk tumours 
was diminished relative to intermediate-risk tumours (high 
risk, ERG median score = 4, IQR 0-11, range 0-18 vs inter-
mediate risk, ERG median score = 5, IQR 0-12, range 0-18; 
Figure 2. Examples of fascin-1 and ETS-related gene (ERG) staining patterns in human prostate carcinomas from the tissue microarray. (A, B) Staining 
for fascin-1; (C, D), staining for ERG. (A) and (C) are from Gleason grade 6 tumours with fascin-1 (A) or ERG (C), staining that is indistinguishable from the 
normal tissue. (B) Example of a Gleason grade 8 tumour with elevated fascin-1 in the stroma and de-differentiated glands. Arrow indicates a 
predominantly fascin-1–negative gland adjacent to 2 fascin-1–positive glands. (D) Example of a Gleason grade 7 tumour with elevated nuclear ERG in 
most cells.
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Figure 4A). These observations are in line with previous studies 
of ERG in prostate tumours.25,26
There was no relationship between fascin-1 positivity and 
ERG score in 183 tumours from the TMA (Figure 4B). 
However, the data are very limited because only 3 tumours had 
a fascin-1 score of 3. Because only a small number of the speci-
mens examined contained more than 10% fascin-1–positive 
tumour cells, the data were also examined by grouping the 
ERG scores into 2 categories of ERG positive (>10% of cells 
with nuclear ERG) and ERG negative. Some ERG-positive 
Figure 3. Assessment of fascin-1 status against clinico-pathological characteristics of human prostate carcinomas from the tissue microarray. (A) 
Relationship between fascin-1 score and Gleason risk classification of the TMA tumour specimens. (B) Relationship between fascin-1 score and tumour 
stage (stage T1 = 12 tumours, T2 = 93 tumours, T3/4 = 106 tumours). (C) Relationship between fascin-1 score and serum PSA levels of the patients prior to 
prostate biopsy. Serum PSA was between 0 and 10 ng/ml for 108 patients; between 10 and 20 ng/ml for 61 patients, and >20 ng/ml for 42 patients. (D) 
Relationship between fascin-1 score and occurrence of biochemical relapse after surgery. The data set includes 19 samples from 18 patients with 
biochemical relapse and 160 from patients who did not undergo biochemical relapse. (E) Relationship between elevated stromal fascin-1 (scored as yes 
or no, see Supplementary Datafile) and Gleason risk classification. Data in (A) to (D) are presented as box and whisker plots, and statistical analyses 
were carried out by Mann-Whitney U test. CI indicates confidence interval; PSA, prostate-specific antigen; TMA, tissue microarray.
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tumours also had a high fascin-1 score, but this did not reach 
statistical significance (ERG-negative tumours had a fascin 
score median of 0, IQR of 0-0, and range of 0-3, whereas 
ERG-positive tumours had a fascin-1 score median of 0, IQR 
of 0-1, and range of 0-3, P = .14; Figure 4C). Thus, the presence 
of fascin-1 in tumour cells does not correlate with nuclear 
ERG.
Conclusions
In this set of prostate carcinomas specimens from WCB, only 
8% of the tumours on the TMA contained >10% fascin-1–pos-
itive carcinoma cells which were typically detected in variable, 
focal patches, adding to the complexity of the scoring. Fascin-1 
was more commonly elevated in cells of the tumour stroma, 
and stromal fascin-1 was significantly elevated in high Gleason 
score versus low Gleason score tumours. The fascin-1 status of 
tumour cells did not correlate with Gleason score, tumour 
stage, serum PSA levels, or biochemical relapse following sur-
gery. In contrast, nuclear ERG was clearly elevated in tumour 
cells and correlated well with Gleason score. Fascin-1 status 
did not correlate with nuclear ERG status. Overall, these 
results indicate that, unlike in breast and colon carcinomas, fas-
cin-1 immunohistochemistry is unlikely to provide a robust 
biomarker for early prediction of aggressive prostate cancers.
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